Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 6
Submit an article Journal homepage
534
Views
33
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group

Matthew D. SeftelDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada; Correspondence[email protected]
,
John KuruvillaDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;
,
Tom KouroukisDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada;
,
Versha BanerjiDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada;
,
Graeme FraserDepartment of Oncology, Juravinski Cancer Centre and McMaster University, Hamilton, ON, Canada;
,
Michael CrumpDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;
,
Rajat KumarDepartment of Medical Oncology and Hematology, CancerCare Manitoba and University of Manitoba, Winnipeg, MB, Canada;
,
Haji I. ChalchalDepartment of Hematology, Allan Blair Cancer Centre, Regina, SK, Canada; ;University of Saskatchewan, Saskatchewan, SK, Canada;
,
Muhammad SalimDepartment of Hematology, Allan Blair Cancer Centre, Regina, SK, Canada; ;University of Saskatchewan, Saskatchewan, SK, Canada;
,
Rob C. LaisterDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada;
,
Susan CrockerDepartment of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada;
,
Spencer B. GibsonResearch Institute of Oncology and Hematology, CancerCare Manitoba and Department of Biochemistry, University of Manitoba, Winnipeg, MB, Canada;
,
Marcia ToguchiAstex Pharmaceuticals, Cambridge, UK;
,
John F. LyonsAstex Pharmaceuticals, Cambridge, UK;
,
Hao XuCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;
,
Jean PowersCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;
,
Joana SederiasCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;
,
Lesley SeymourCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;
&
Annette E. HayCanadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada; ;Department of Medicine, Queen’s University, Kingston, ON, Canada
 show all
Pages 1358-1365 | Received 04 May 2016, Accepted 11 Sep 2016, Published online: 17 Oct 2016

References

  • Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99:965–972.
  • Dreyling M, Geisler C, Hermine O, et al. ESMO Guidelines Working Group. Ann Oncol. 2014;25:iii83–iii92.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • Wang ML, Rule SM, Goy P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
  • Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130–146.
  • Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519M, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009;8:324–332.
  • Santo L, Vallet S, Hideshima T, et al. AT7519M, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010;29:2325–2336.
  • Chen EX, Hotte S, Hirte H, et al. A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. Br J Cancer. 2014;111:2262–2267.
  • Roos G, Kröber A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. 2008;111:2246–2252.
  • Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. International Workshop on Chronic Lymphocytic Leukemia. Blood. 2008;111:5446–5456.
  • Ji J, Mold DR, Blum KA, et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res. 2013;19:1269–1280.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–586.
  • Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38:143–151.
  • Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009;37:e21. doi: 10.1093/nar/gkn1027.
  • Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30:2820–2822.
  • Flynn J, Jones J, Johnson AJ, et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015;29:1524–1529.
  • Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:1740–1745.
  • Mahadevan D, Plummer R, Squires MS, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol. 2011;22:2137–2143.
  • Younes A, Hagenbeek A, Coiffier, et al. Optimising the lymphoma response criteria in the era of targeted therapy. Lancet Oncol. 2011;12:616–617.
  • Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–3405.
  • Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
  • Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.